Related Experiment Video
Updated: Feb 26, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Furin Inhibition Protects Against Acute Lung Injury in a Mouse Model of Pseudomonas Aeruginosa Infection
Olivier Bernard1, Michael Kwon1, Mark R Looney1
1Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco.
Abstract:
Pseudomonas aeruginosa (PA) is responsible for significant morbidity and mortality particularly in patients with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF) as well as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The rise of antibiotic-resistant PA strains necessitates alternative treatment strategies. Among the different toxins secreted by PA, Exotoxin-A (Exo-A) becomes cytotoxic when cleaved by furin. This study investigates the therapeutic potential of furin inhibitor BOS-318 in mitigating acute lung injury induced by Exo-A and PA infection. Furin inhibition significantly improved survival rates and reduced lung injury in mouse pneumonia models using Exo-A and PA103. Additionally, BOS-318 accelerated bacterial clearance in vivo, and increased phagocytosis by alveolar macrophages. Bulk RNA-seq done on whole lung homogenate at 6 h revealed an immune profile with decreased natural killer (NK) cell signaling in the BOS-318-treated group, possibly due to a decrease in NK recruitment observed at 24 h, suggesting a role of furin in shaping the immune response. Moreover, administration of BOS-318 as a therapeutic strategy results in a protection of the lung epithelium. Overall, our findings demonstrate that furin inhibition protects against PA-induced acute lung injury and hastens bacterial clearance. These results are the first to characterize furin inhibition in animal models and supports its potential use as an adjunctive therapeutic strategy for treating PA infections.
Insights
Furin inhibition with BOS-318 improves survival and reduces lung injury in Pseudomonas aeruginosa pneumonia mouse models. This strategy also enhances bacterial clearance and protects lung epithelium, showing therapeutic potential.
Area of Science:
- Microbiology
- Immunology
- Pharmacology
Background:
- Pseudomonas aeruginosa (PA) causes severe lung infections, including pneumonia, and antibiotic resistance is a growing concern.
- Exotoxin-A (Exo-A) from PA is a key virulence factor, becoming cytotoxic after furin cleavage.
- Novel therapeutic strategies are needed to combat PA infections and their associated lung injury.
Purpose of the Study:
- To investigate the therapeutic potential of the furin inhibitor BOS-318 against acute lung injury induced by Exo-A and PA.
- To evaluate the impact of furin inhibition on survival, lung injury, bacterial clearance, and immune responses in vivo.
Main Methods:
- Mouse models of pneumonia were established using Exo-A and PA103.
- Mice were treated with the furin inhibitor BOS-318.
- Survival rates, lung injury, bacterial load, alveolar macrophage phagocytosis, and lung immune cell profiles (via bulk RNA-seq) were assessed.
Main Results:
- Furin inhibition significantly improved survival rates and reduced lung injury in PA-infected mice.
- BOS-318 treatment accelerated bacterial clearance and enhanced phagocytosis by alveolar macrophages.
- RNA-seq revealed altered immune profiles, including decreased natural killer (NK) cell signaling, and protection of lung epithelium.
Conclusions:
- Furin inhibition is a promising adjunctive therapeutic strategy for treating Pseudomonas aeruginosa infections.
- Targeting furin activity can mitigate PA-induced acute lung injury and improve bacterial clearance.
- These findings provide the first characterization of furin inhibition in animal models for PA infection treatment.
